Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for InnoCare Pharma's Debt-to-EBITDA or its related term are showing as below:
INCPF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.07 Med: -1.55 Max: 78.14
Current: 1.56
During the past 9 years, the highest Debt-to-EBITDA Ratio of InnoCare Pharma was 78.14. The lowest was -4.07. And the median was -1.55.
INCPF's Debt-to-EBITDA is ranked worse than 51.91% of 314
companies
in the Biotechnology industry
Industry Median: 1.41
vs INCPF: 1.56
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
InnoCare Pharma Debt-to-EBITDA Related Terms
InnoCare Pharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for InnoCare Pharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INCPF vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, InnoCare Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
InnoCare Pharma (INCPF) has a Debt-to-EBITDA of 0.83 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on InnoCare Pharma. According to the industry distribution chart, InnoCare Pharma ranks #163 out of 314 companies in the Biotechnology industry, placing it in the top 51.9%.
Is InnoCare Pharma's Debt-to-EBITDA too high?
InnoCare Pharma's current Debt-to-EBITDA is 0.83. The Biotechnology industry median Debt-to-EBITDA is 1.41. InnoCare Pharma's value of 0.83 is 41.1% below this industry median. Based on the distribution chart, InnoCare Pharma ranks #163 out of 314 companies in the Biotechnology industry, which is below the industry midpoint. Overall, InnoCare Pharma has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #163 out of 314 companies for Debt-to-EBITDA. This places InnoCare Pharma in the lower half of its industry. The industry median Debt-to-EBITDA is 1.41. InnoCare Pharma's value of 0.83 is 41.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.41, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCare Pharma's current Debt-to-EBITDA of 0.83 is 41.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on InnoCare Pharma. For the Biotechnology industry, the median Debt-to-EBITDA is 1.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCare Pharma's current Debt-to-EBITDA is 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
InnoCare Pharma (INCPF) has a current Debt-to-EBITDA of 0.83. The stock's GF Value™ is $2.32, compared to a current price of $1.55 — trading 33.2% below its estimated fair value. The current Debt-to-EBITDA is 0.83 and 41.1% below the Biotechnology industry median of 1.41. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For InnoCare Pharma (INCPF), the current Debt-to-EBITDA is 0.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (INCPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of $1.55 is trading 33.2% below its estimated GF Value™ of $2.32.
Key valuation signals for INCPF:
Debt-to-EBITDA: 0.83
GF Value™: $2.32 vs. price of $1.55 (33.2% below fair value)
Industry Position: 41.1% below the Biotechnology median (#163 of 314)
No single metric tells the full story. See the INCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score
Get the complete analysis for INCPF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCPF has been successfully added to your 
